PMID- 35877241
OWN - NLM
STAT- MEDLINE
DCOM- 20220727
LR  - 20220908
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 29
IP  - 7
DP  - 2022 Jul 8
TI  - Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor 
      Associated with the Therapeutic Response and the Continuation of Atezolizumab 
      plus Bevacizumab Combination Therapy for Patients with Unresectable 
      Hepatocellular Carcinoma.
PG  - 4799-4810
LID - 10.3390/curroncol29070381 [doi]
AB  - BACKGROUND: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as 
      the first-line systemic therapy for patients with unresectable hepatocellular 
      carcinoma (u-HCC). This study aimed to investigate the predictive factors of 
      therapeutic response and the continuation of ATZ + BV treatment for u-HCC in a 
      real-world setting. METHODS: This retrospective study was conducted between 
      January 2021 and April 2022. Twenty-eight patients with u-HCC, who were treated 
      with ATZ + BV, were assessed for their treatment response, continuation, and 
      adverse events (AEs). RESULTS: Among the 28 patients, 24 were evaluated at the 
      first imaging. The objective response rate (ORR) was 29.2% (n = 7), and 54.2% (n 
      = 13) on the response evaluation criteria in solid tumors (RECIST 1.1) and in the 
      modified RECIST (mRECIST) guidelines, respectively. Comparing the objective 
      response (OR) group (n = 13) and the non-OR group (n = 11), the modified 
      albumin-bilirubin (mALBI) grades 1 and 2a were found to be significant predictive 
      factors for OR (p = 0.021) in the mRECIST guidelines. Among the 28 patients, 17 
      discontinued their treatment due to AEs. Comparing the treatment continuation (n 
      = 11) and discontinuation groups (n = 17), a Child-Pugh score of five points (p = 
      0.009) and mALBI grades 1 and 2a (p = 0.020) were predictive factors with 
      significant differences. CONCLUSIONS: Pretreatment mALBI grades 1 and 2a were the 
      important predictive factors associated with the therapeutic response and the 
      therapeutic continuation of ATZ + BV for patients with u-HCC.
FAU - Tanaka, Takashi
AU  - Tanaka T
AUID- ORCID: 0000-0002-9310-1294
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Takata, Kazuhide
AU  - Takata K
AUID- ORCID: 0000-0002-0255-2904
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Yokoyama, Keiji
AU  - Yokoyama K
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Fukuda, Hiromi
AU  - Fukuda H
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Yamauchi, Ryo
AU  - Yamauchi R
AUID- ORCID: 0000-0003-3632-8326
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Fukunaga, Atsushi
AU  - Fukunaga A
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Shakado, Satoshi
AU  - Shakado S
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Sakisaka, Shotaro
AU  - Sakisaka S
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
FAU - Hirai, Fumihito
AU  - Hirai F
AD  - Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka 
      University, Nanakuma 7-45-1, Fukuoka 814-0180, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220708
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
RN  - 0 (Albumins)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - RFM9X3LJ49 (Bilirubin)
SB  - IM
MH  - Albumins/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab/pharmacology/therapeutic use
MH  - Bilirubin/therapeutic use
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Humans
MH  - *Liver Neoplasms/drug therapy
MH  - Retrospective Studies
PMC - PMC9324802
OTO - NOTNLM
OT  - adverse events
OT  - atezolizumab
OT  - bevacizumab
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitors
COIS- The authors declare no conflict of interest related to this study.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/28 06:00
PMCR- 2022/07/08
CRDT- 2022/07/25 12:43
PHST- 2022/05/24 00:00 [received]
PHST- 2022/07/05 00:00 [revised]
PHST- 2022/07/06 00:00 [accepted]
PHST- 2022/07/25 12:43 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/28 06:00 [medline]
PHST- 2022/07/08 00:00 [pmc-release]
AID - curroncol29070381 [pii]
AID - curroncol-29-00381 [pii]
AID - 10.3390/curroncol29070381 [doi]
PST - epublish
SO  - Curr Oncol. 2022 Jul 8;29(7):4799-4810. doi: 10.3390/curroncol29070381.